Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone. (Q38823747)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 October 2015

Language	Label	Description	Also known as
English	Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone.	scientific article published on 29 October 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Beatrice Schuler-Thurner

11

object named as

Beatrice Schuler-Thurner

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

10

object named as

Gerold Schuler

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

9

object named as

Hinrich Abken

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Katrin Birkholz

2

object named as

Katrin Birkholz

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Michael Schwenkert

4

object named as

Michael Schwenkert

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Christian Krug

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Alexander Paulus

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Patrick Schmidt

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Nicole Hoffmann

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Andreas Hombach

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Georg Fey

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

29 October 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

64

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1623-1635

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Chimeric antigen receptor therapy for cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Transiently redirected T cells for adoptive transfer.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Synthetic messenger RNA as a tool for gene therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Treatment of advanced leukemia in mice with mRNA engineered T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Tuning tumor-specific T-cell activation: a matter of costimulation?

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Immunochemical characterization of a human high molecular weight ? melanoma associated antigen identified with monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

The NG2 chondroitin sulfate proteoglycan: role in malignant progression of human brain tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Unexpected expression of the 250 kD melanoma-associated antigen in human sarcoma cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibodies MK2-23. Experimental studies and clinical trials in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Human melanoma/NG2 chondroitin sulfate proteoglycan is expressed in the sarcolemma of postnatal human skeletal myofibers. Abnormal expression in merosin-negative and Duchenne muscular dystrophies.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Targeting pericytes diminishes neovascularization in orthotopic uveal melanoma in nerve/glial antigen 2 proteoglycan knockout mouse

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

In vivo studies of pharmacokinetics and efficacy of Bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Eradication of melanomas by targeted elimination of a minor subset of tumor cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Human Neuroectoderm-Derived Cell Line Secretes Fibronectin that Shares the HNK-1/10C5 Carbohydrate Epitope with Neural Cell Adhesion Molecules

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Production and Characterization of Monoclonal Antibody to a Melanoma Specific Glycoprotein

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Large volume flow electroporation of mRNA: clinical scale process

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Overcoming the toxicity hurdles of genetically targeted T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Costimulation tunes tumor-specific activation of redirected T cells in adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1767-4

21 January 2018

Identifiers

10.1007/S00262-015-1767-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26515978%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38823747&oldid=2202118796"